Cellmid Limited

Cellmid 'on track for record revenues' in FY19, targeting profitability in FY20

Cellmid Limited (ASX:CDY) CEO Maria Halasz tells Proactive Investors the major achievements since raising $10 million in September last year, and details the next phases of growth.

Cellmid is a life sciences company with a consumer business that has consistently delivered double digit revenue growth and is heading towards profitability. It is also the owner and developer of the largest intellectual property portfolio around midkine; a drug target indicated in cancer, inflammatory diseases and fibrosis.

Quick facts: Cellmid Limited

Price: $0.22

Market: ASX
Market Cap: $18.39 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...



Cellmid Limited outlines key components for FY2020 growth strategy

Cellmid Limited (ASX:CDY) chief executive officer and managing director Maria Halasz updates Proactive Investors on the company’s key components for its FY2020 growth strategy, which includes an exciting new global product to assist ageing hair.  Cellmid is a listed company with health...

on 14/8/19

2 min read